3 unknown, 2 active not recruiting, 2 recruiting, 1 completed. 10 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 10 | Unknown 3, Active not recruiting 2, Recruiting 2, Completed 1, Not yet recruiting 1, Terminated 1 |
Follow fluzoparib: new trials by email Literature Review of fluzoparib trials Research Report on fluzoparib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian Cancer Fluzoparib Capsules, Apatinib Mesylate Tablets - Ovarian Cancer | Phase 3 | Not yet recruiting | The First Affiliated Hospital of Xiamen University | 37 | 2024-12-01 | 2024-01-03 |
| Fluzoparib in Combination With Apatinib Mesylate for Maintenance Therapy in Stage III-IV Ovarian Cancer Fluzoparib, Apatinib Mesylate - Epithelial Ovarian Cancer, Efficacy | Phase 3 | Unknown | Anhui Provincial Hospital | 51 | 2024-10-01 | 2024-08-06 |
| PARP Inhibitor With CDK4/ 6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer Fluzoparib, Dalpiciclib, Fulvestrant/AI - Breast Cancer Metastatic | Phase 3 | Active not recruiting | Zhimin Shao | 307 | 2024-09-01 | 2024-09-25 |
| Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer Fluzoparib, Apatinib Mesylate, Capecitabine tablets - Fludzoparib" and Anti-angiogenic, HRD-positive/HER2-negative Advanced Breast Cancer | Phase 3 | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 200 | 2024-06-12 | 2025-08-15 |
| Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01) Fluzoparib, Anastrozole, Letrozole - Breast Cancer | Phase 3 | Recruiting | Fudan University | 766 | 2023-06-01 | 2024-02-08 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer Fuzuloparib , Abiraterone acetate and Prednisone, Fuzuloparib Placeboļ¼ Abiraterone acetate and Prednisone - Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase 3 | Active not recruiting | Jiangsu HengRui Medicine Co., Ltd. | 496 | 2021-03-18 | 2024-12-31 |
| A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy Fluzoparib, Placebo - Metastatic Pancreatic Cancer | Phase 3 | Terminated | Jiangsu HengRui Medicine Co., Ltd. | 5 | 2020-08-19 | 2024-03-28 |
| A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation Fluzoparib; Apatinib, Fluzoparib, Physician's choice chemotherapy - Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation | Phase 3 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 474 | 2020-07-13 | 2020-08-10 |
| A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy Fluzoparib; Apatinib, Fluzoparib, Placebo - Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 690 | 2020-06-02 | 2022-04-25 |
| A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients Fluzoparib capsules, Placebo capsules - Ovarian Cancer | Phase 3 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 252 | 2019-04-30 | 2025-07-03 |
Ovarian Neoplasms (3) · Breast Neoplasms (1) · Carcinoma, Ovarian Epithelial (1) · Fallopian Tube Neoplasms (1) · Pancreatic Neoplasms (1)
Jiangsu HengRui Medicine Co., Ltd. (5) · Anhui Provincial Hospital (1) · Fudan University (1) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1) · The First Affiliated Hospital of Xiamen University (1) · Zhimin Shao (1)
China (8) · Australia (1) · Belgium (1) · Czechia (1) · France (1) · Hungary (1) · Poland (1) · Russia (1) · South Korea (1) · Spain (1) · Taiwan (1) · United Kingdom (1) · United States (1)
Jianli Zhao (1) · Lingying Wu (1) · Ying Zhou, MD (1) · Yupei Zhao, Ph.D (1)